Abstract
In recent years, chimeric antigen receptor (CAR) modified T-cell (CAR-T) immunotherapy has achieved great success in cancer treatment, especially in some hematologic malignancies. Multiparametric flow cytometry (MFC) is a key immunologic tool and plays an important role in every step of CAR-T design, development, and clinical trials. This chapter discusses the application and new developments of MFC in CAR-T, including the selection of CAR-T targets, the enrollment of patients, the detection of minimal/measurable residual disease (MRD), the quality evaluation of CAR-T product, the detection of immune cell subsets and cytokines, and the study of immune checkpoint and immune suppressive microenvironment.